Advances in covalent drug discovery
L Boike, NJ Henning, DK Nomura - Nature Reviews Drug Discovery, 2022 - nature.com
Covalent drugs have been used to treat diseases for more than a century, but tools that
facilitate the rational design of covalent drugs have emerged more recently. The purposeful …
facilitate the rational design of covalent drugs have emerged more recently. The purposeful …
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
L Huang, S Jiang, Y Shi - Journal of hematology & oncology, 2020 - Springer
Tyrosine kinases are implicated in tumorigenesis and progression, and have emerged as
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
major targets for drug discovery. Tyrosine kinase inhibitors (TKIs) inhibit corresponding …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Oral mucositis: the hidden side of cancer therapy
Inflammation response of epithelial mucosa to chemo-radiotherapy cytotoxic effects leads to
mucositis, a painful side effect of antineoplastic treatments. About 40% of the patients treated …
mucositis, a painful side effect of antineoplastic treatments. About 40% of the patients treated …
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
M Yuan, LL Huang, JH Chen, J Wu, Q Xu - Signal transduction and …, 2019 - nature.com
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer …
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Y Qian, Y Gong, Z Fan, G Luo, Q Huang… - Journal of hematology & …, 2020 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …
Evaluating eligibility criteria of oncology trials using real-world data and AI
There is a growing focus on making clinical trials more inclusive but the design of trial
eligibility criteria remains challenging,–. Here we systematically evaluate the effect of …
eligibility criteria remains challenging,–. Here we systematically evaluate the effect of …
Squamous cell lung cancer: Current landscape and future therapeutic options
Squamous cell lung cancers (lung squamous cell carcinomas [LUSCs]) are associated with
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …
high mortality and a lack of therapies specific to this disease. Although recurrent molecular …